Burden of disease progression in patients with multiple myeloma in the US-Reference-Cited by-同舟云学术

Burden of disease progression in patients with multiple myeloma in the US

Published:2019-08-07 Issue:1 Volume:61 Page:47-55
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Hagiwara May¹,Panjabi Sumeet²,Delea Tom¹,Yucel Emre³,Fonseca Rafael⁴

Affiliation:

1. Policy Analysis Inc, Brookline, MA, USA;

2. Amgen Inc San Francisco, South San Francisco, CA, USA;

3. Amgen Inc, Thousand Oaks, CA, USA;

4. Mayo Clinic Scottsdale, Scottsdale, AZ, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2019.1648802

Reference16 articles.

1. Atlanta: American Cancer Society. Cancer facts & figures; 2018; [cited 2018 Nov 29]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf

2. National Comprehensive Cancer Network. The NCCN guidelines® version 2. Multiple myeloma; 2019; [cited 2018 Nov 29]. Available from: https://www.nccn.org/professionals/physician_gls/PDF/myeloma.pdf

3. Retrospective study of frequency and cost of multiple myeloma (MM) complications and treatment (Tx) related adverse events (AEs).

4. Health Care Costs and Resource Utilization, Including Patient Burden, Associated With Novel-Agent-Based Treatment Versus Other Therapies for Multiple Myeloma: Findings Using Real-World Claims Data

5. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circulating sRANKL, Periostin, and Osteopontin as Biomarkers for the Assessment of Activated Osteoclastogenesis in Myeloma Related Bone Disease;Cancers;2023-11-24

2. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis;Journal of Managed Care & Specialty Pharmacy;2023-08

3. Early Intervention With a Curative Intent Through an Intensive Therapy Versus Immunologic Disease Control Using a Minimal Intensity Approach in the Management of High-risk Smoldering Multiple Myeloma: A Systematic Review of Evidence From Clinical Trials;Clinical Lymphoma Myeloma and Leukemia;2023-01

4. High hospital-related burden of treatment for multiple myeloma patients: outcomes of a feasibility study using reimbursement data from electronic health records;Health Policy and Technology;2022-12

5. Practice patterns and outcomes for triple-class exposed patients with relapsed/refractory multiple myeloma in Japan;Future Oncology;2022-11